Dr. George J. Kahaly |
Fig. 01 -
Title Slide
Fig. 02 -
Disclosure
Fig. 03 -
TSH-R Antibody Assays
Fig. 04 -
Binding versus Bio-assays
Fig. 05 -
Varieties
Fig. 06 -
Diagnostic Modalities
Fig. 07 -
Baseline Serum
Fig. 08 -
TSI Assay Utilization
Fig. 09 -
TSAB Bioassay Principle
Fig. 10 -
Mc4 TSHR
Fig. 11 -
Precision
Fig. 12 -
Novel Chimeric
Fig. 13 -
Sensitivity and Specificity
Fig. 14 -
Dose Response Curve
Fig. 15 -
Study Design
Fig. 16 -
Normal Serum
Fig. 17 -
Predictive Value
Fig. 18 -
Predict the Course
Fig. 19 -
TSI to TBI
Fig. 20 -
Bioassays
Fig. 21 -
Ranges of Bovine
Fig. 22 -
Blocking Activity
Fig. 23 -
K1-70 mAb
Fig. 24 -
Differentiates
Fig. 25 -
Different Ratios
Fig. 26 -
TSAb and TBAb
Fig. 27 -
173 TBAb
Fig. 28 -
Dose-Response Curves
Fig. 29 -
Analytical Performance
Fig. 30 -
Comparison
Fig. 31 -
ELISA and ABA
Fig. 32 -
Positivity of Low
Fig. 33 -
Positivity of Moderate
Fig. 34 -
Positivity of High
Fig. 35 -
Positivity in TBAb+
Fig. 36 -
Dilution Protocol
Fig. 37 -
Positivity in Untreated
Fig. 38 -
Positivity in GD
Fig. 39 -
Binding Assay Results
Fig. 40 -
TBAb Bioassay
Fig. 41 -
TSAb Bioassay
Fig. 42 -
Detection
Fig. 43 -
Kronus Elisa Assay
Fig. 44 -
Positivity in pts.
Fig. 45 -
Summary and Conclusions
TODO, let Pete know of any updates to this content
Six (6) provocative statements concerning clinical treatment of IBD. Each statement is presented as 5 steps:Step 1: the statement & introduction, + 5 possible opinions of that statement -- please choose one
Step 2: a graph of an international survey’s opinions of that statement
Step 3: a literature review for that statement
Step 4: a graph comparing the faculty's vs an international survey’s opinions, + faculty discussion
Step 5: a brief faculty summary, plus the list of references.
Please click on any Statement or any Step tab to read this publication in the order you prefer.